TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00039130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 ug/kg/day sub Q injection day 7 until ANC\>5000/ul courses II-VII

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Day 8 course II 50 mg/sq m IV infusion: d 8 course IV \& VI 375mg/sq m IV Day 10 course II: 325 mg/sq m IV infusion Day 12 course II: 375 mg/sq m IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 1 g/sq m/day IV infusion Days 4 \& 5, courses II, IV, VI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 10mg/sq m PO or IV Days 1-5 courses II-VII

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 25 mg/sq m/day IV infusion Days 4 \& 5 courses III,V, VII

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 80 mg/sq m/day IV infusion Days 4 \& 5 courses II, IV, VI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: 800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX \<10nM, courses II-VII

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 1.5 g/sq m IV infusion Day 1 courses II-VII
Study: NCT04047914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic therapy
Description: Application 0.01% methylene blue with sterile swabs in each nostril with a 10-minute pre-irradiation~• Light-emitting diode (λ = 660 nm), for 300 seconds, with an irradiance of 400 mW / cm2
Study: NCT03802240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 IV Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m2 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 IV Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo1
Description: Placebo1 IV Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo2
Description: Placebo2 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo2
Description: Placebo2 IV Q3W
Study: NCT02685124

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orange juice
Description: Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
Study: NCT01352013

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 (oil)
Description: 5ml daily with breakfast for 56 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fatty Acids (placebo)
Description: 5ml daily with breakfast for 56 days.
Study: NCT04151719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone bromide (MNTX)
Description: Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
Study: NCT01148576

Intervention type: DRUG
Group type: OTHER
Intervention: entecavir
Description: entecavir 0.5 mg qd for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir
Description: entecavir 0.5 mg qd for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: essentiale + entecavir
Description: entecavir 0.5 mg qd for 12 months，Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
Study: NCT03366155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 500 mg/m2, IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic SynchroMed II Pump
Description: implanted Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter
Study: NCT00039130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60 mg/sq m PO/day Days 1-7 course I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 2 mg IV push Day 1 courses II-VII

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 300 mg/day PO Days 1-14, course I
Study: NCT04047914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: Performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
Study: NCT03545035

Intervention type: DRUG
Intervention: idelalisib and rituximab
Description: patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab
Study: NCT02361294

Intervention type: OTHER
Intervention: Blood samples

Intervention type: OTHER
Intervention: Blood samples
Study: NCT02901964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip Abductor Exercise
Description: 12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
Study: NCT00908713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9% 10 mL every 12 h for 5 days
Study: NCT04615481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elliptical Training Group
Description: The training program will be consisted of total 30 minutes of elliptical cross training (5 minutes warm up + Progressive Training up to 20 minutes of elliptical cross training + 5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergo-metric Training Group
Description: The training program will be consisted of total 30 minutes of ergometric training (5 minutes warm up + Progressive Training up to 10 minutes of upper limb ergometric training + Progressive Training up to 10 minutes of lower limb ergometric training+5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
Study: NCT01148576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E + entecavir
Description: entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
Study: NCT02901964

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip Aductor Exercise
Description: 12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
Study: NCT04603235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual-based Art Therapy
Description: This is a manual-based treatment and consists of 10 one-hour weekly sessions. The treatment consist of detailed guidelines based on phenomenological art therapy. The sessions follow the same structure: Introduction, short relaxation, art-making, reflections about the image, and conclusions. Examples of comprised art tasks; lifeline, emotional scribbles, and different roles. The art tasks served as a prompt for painting.
Study: NCT04441710

Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will be invited to complete a detailed questionnaire to collect prospectively and retrospectively data around the CoViD19 serological screening.

Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will be invited to complete a detailed questionnaire to collect prospectively and retrospectively data around the CoViD19 serological screening.
Study: NCT02520713

Intervention type: GENETIC
Intervention: Genetic testing and GAIN report
Description: All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.
Study: NCT01707095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unbundling of cords
Description: The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundling of cords
Description: The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
Study: NCT04421612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-mestring (co-coping)
Description: 8 modules with the aim to reduce stress, increase coping of social isolation and coping with the consequences of reduced positive experiences

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-mestring (co-coping)
Description: 8 modules with the aim to reduce stress, increase coping of social isolation and coping with the consequences of reduced positive experiences
Study: NCT02262676

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Patients treated by Physicians under approved local prescriptions
Study: NCT04095793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ampreloxetine
Description: Oral tablet, QD
Study: NCT02482649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EAA/T
Description: bi-weekly for 12weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: dosage adjustment according to clinical effectiveness, QD for 12weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: dosage adjustment according to clinical effectiveness, QD or BID, for 12weeks
Study: NCT01113788

Intervention type: DEVICE
Intervention: tricuspid isthmus imaging with Cartosound
Description: tricuspid isthmus imaging with Cartosound
Study: NCT04144179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 1
Description: Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 2
Description: Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 3
Description: Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 4
Description: Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent RIV with 2018-2019 NH H3 strain
Description: Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
Study: NCT03572062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Adjuvanted RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Adjuvanted RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Adjuvanted RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Adjuvanted RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00279305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD20 (rituximab)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo intravenous infusion
Study: NCT04303832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye exercises
Description: Eye exercises for correcting eye deviation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: eye glasses
Description: Eye glasses for correcting eye deviation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eye glasses
Description: Eye glasses for correcting eye deviation
Study: NCT04441710

Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will be invited to complete a detailed questionnaire to collect prospectively and retrospectively data around the CoViD19 serological screening.
Study: NCT00685672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenalin
Description: adrenalin 2 microgram pr ml placebo
Study: NCT00272480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine/lamivudine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT01675206

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 supplementation
Study: NCT00685672

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Saline instead of adrenaline in the epidural mixture
Study: NCT04053361

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.
Study: NCT01013090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxyethyl starch
Description: Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxyethyl starch
Description: Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxyethyl starch
Description: Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
Study: NCT05702736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: logotherapy-based intervention
Description: Logotherapy-based intervention was administered to the individuals in the intervention group as a total of eight sessions, once a week.
Study: NCT01229280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Single dose 7.5 mg tablets of darifenacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darifenacin
Description: Single dose 7.5 mg tablets of Darifenacin
Study: NCT04481854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cricoid pressure
Description: cricoid pressure during laryngoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left paratracheal pressure
Description: left paratracheal pressure during laryngoscopy
Study: NCT04662125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine, paracetamol tablet
Description: oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral prednisolone
Description: patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days. .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral pregabalin
Description: patients who received conservative treatment as control group together with oral tablet pregabalin 150 mg twice per day for three days.
Study: NCT02657291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound guided block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided block
Study: NCT00958750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minoxidil
Description: the investigators compared two different formulations and concentrations of minoxidil in this study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minoxidil
Description: the investigators compared two different formulations and concentrations of minoxidil in this study
Study: NCT02733471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03051217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use Q2W

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use
Study: NCT01024062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
Study: NCT00610077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
Study: NCT03828786

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratching
Description: Endometrial Biopsy by aspiration with a pipelle
Study: NCT03777423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK framework partial dentures
Description: Polymer-based framework recently introduced made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cobalt- chromium framework partial dentures
Description: It's a bio-compatible metal used in thin sections so less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and resistance to corrosion.Drawbacks of metal frameworks can include hypersensitivity, aesthetics because of metal metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production
Study: NCT03674567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX475
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX475
Description: tablet